Jerusalem, 8 May (IANS). Israeli scientists have discovered a special genetic fingerprint, which can be ascertained whether the immunotherapy used in the treatment of cancer will affect a patient.
This research has been done by Israeli’s ‘Technion – Israel Institute of Technology’. According to the Xinhua News Agency report, scientists say that this discovery will help in giving immunotherapy better according to every patient. Immunotherapy is a modern treatment, which strengthens the body’s immune system to fight cancer so that it can identify and destroy cancer cells. But a big problem in this is that every patient has different effects. Some patients do not benefit, but rather reverse side effects.
Therefore, scientists were trying to find out how can a patient work on whether this treatment would work or not.
In the study published in Journal Cell Genomics Research, scientists examined the T-cell clone. These T-cells are part of the body’s security system and identify a particular disease and fight it.
To achieve the required target, the team made a large meta-analysis using single-cell RNA sequencing and T-cell receptor sequential data from cancer patients. These patients were undergoing treatment with immunotherapy. He saw samples of cancer patients and saw that patients who show good effects of immunotherapy have a special kind of genetic identity in T-cells. Due to this identity, their immune system becomes more active during treatment.
Another important thing came to know that some T-cells in their body are present in both blood and tumors in their body. According to scientists, a better effect of immunotherapy is when only the T-cells inside the tumor are activated, not the T-cells present in both the blood and the tumor.
With this discovery, the impact of immunotherapy in future will be better predicted than before and the treatment will be made more effective.
-IANS
AS/
